Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

The Kingdom of Saudi Arabia will host the Middle East edition of the “BIO / CPHI” Biotechnology and Pharmaceutical ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Three mid-cap biotechs have become prime acquisition targets, but only one offers what big pharma is hunting for most.

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

Innovative Pharmaceutical Biotech (HK:0399) has released an update. Innovative Pharmaceutical Biotech Limited has entered into a Memorandum of Understanding to potentially acquire a majority stake in ...

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large ...

Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

DUBLIN--(BUSINESS WIRE)--The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2020-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...

They have at least one thing in common: An exciting pipeline.